BARD1 Life Sciences (ASX: BD1)
BARD1 Life Sciences (ASX: BD1) is an Australian company developing novel diagnostics and therapeutics for unmet needs in cancer. www.bard1.com
Bard1 Life Sciences and Sienna Cancer Diagnostics announce $23.7m merger
Medical technology companies Bard1 Life Sciences (ASX: BD1) and Sienna Cancer Diagnostics (ASX: SDX) will stage a $23.7 million merger to create...
BARD1 develops world-first blood test for breast cancer detection; offers high diagnostic accuracy
Perth-based biotech company BARD1 Life Sciences (ASX: BD1) has developed a world-first blood test for the early detection of breast cancer, clai...
BARD1 Life Sciences’ ovarian cancer test detects disease in high-risk women
BARD1 Life Sciences (ASX: BD1) has validated the commercial potential of its ovarian cancer screening test after new research revealed the test’...
BARD1 Life Sciences en route to delivering better ovarian cancer screening
BARD1 Life Sciences (ASX: BD1), a biotechnology company developing a non-invasive cancer diagnostics test for ovarian cancer, announced encourag...
BARD1 leverages ProcartaPlex technology to accelerate development of ovarian cancer detection
Australian biotech company BARD1 Life Sciences (ASX: BD1) has entered into an assay development agreement with Thermo Fisher Scientific for cust...
BARD1 Life Sciences expands success in non-invasive ovarian cancer test, moves to commercialisation
BARD1 Life Sciences (ASX: BD1) has pronounced additional success for its BARD1-Ovarian test after an independent test confirmed the non-invasive...
BARD1 Life Sciences receives timely Japanese patent
Australian biotech company BARD1 Life Sciences (ASX: BD1) has been granted an important patent for cancer diagnostics in Japan.
The Japan Pat...
BARD1 reports success in non-invasive ovarian cancer detection study
Biotech stock BARD1 Life Sciences (ASX: BD1) has achieved positive results in its non-invasive ovarian cancer diagnostic study.
The OC-400 st...